201 related articles for article (PubMed ID: 21464250)
1. In vitro and in vivo profiles of ACH-702, an isothiazoloquinolone, against bacterial pathogens.
Pucci MJ; Podos SD; Thanassi JA; Leggio MJ; Bradbury BJ; Deshpande M
Antimicrob Agents Chemother; 2011 Jun; 55(6):2860-71. PubMed ID: 21464250
[TBL] [Abstract][Full Text] [Related]
2. In vitro and in vivo antibacterial activities of heteroaryl isothiazolones against resistant gram-positive pathogens.
Pucci MJ; Cheng J; Podos SD; Thoma CL; Thanassi JA; Buechter DD; Mushtaq G; Vigliotti GA; Bradbury BJ; Deshpande M
Antimicrob Agents Chemother; 2007 Apr; 51(4):1259-67. PubMed ID: 17242152
[TBL] [Abstract][Full Text] [Related]
3. Dual targeting of DNA gyrase and topoisomerase IV: target interactions of heteroaryl isothiazolones in Staphylococcus aureus.
Cheng J; Thanassi JA; Thoma CL; Bradbury BJ; Deshpande M; Pucci MJ
Antimicrob Agents Chemother; 2007 Jul; 51(7):2445-53. PubMed ID: 17502409
[TBL] [Abstract][Full Text] [Related]
4. In vitro activities of novel nonfluorinated quinolones PGE 9262932 and PGE 9509924 against clinical isolates of Staphylococcus aureus and Streptococcus pneumoniae with defined mutations in DNA gyrase and topoisomerase IV.
Jones ME; Critchley IA; Karlowsky JA; Blosser-Middleton RS; Schmitz FJ; Thornsberry C; Sahm DF
Antimicrob Agents Chemother; 2002 Jun; 46(6):1651-7. PubMed ID: 12019071
[TBL] [Abstract][Full Text] [Related]
5. Bactericidal activity of ACH-702 against nondividing and biofilm Staphylococci.
Podos SD; Thanassi JA; Leggio M; Pucci MJ
Antimicrob Agents Chemother; 2012 Jul; 56(7):3812-8. PubMed ID: 22547614
[TBL] [Abstract][Full Text] [Related]
6. Novel Bacterial Topoisomerase Inhibitors with Potent Broad-Spectrum Activity against Drug-Resistant Bacteria.
Charrier C; Salisbury AM; Savage VJ; Duffy T; Moyo E; Chaffer-Malam N; Ooi N; Newman R; Cheung J; Metzger R; McGarry D; Pichowicz M; Sigerson R; Cooper IR; Nelson G; Butler HS; Craighead M; Ratcliffe AJ; Best SA; Stokes NR
Antimicrob Agents Chemother; 2017 May; 61(5):. PubMed ID: 28223393
[TBL] [Abstract][Full Text] [Related]
7. Activities of trovafloxacin compared with those of other fluoroquinolones against purified topoisomerases and gyrA and grlA mutants of Staphylococcus aureus.
Gootz TD; Zaniewski RP; Haskell SL; Kaczmarek FS; Maurice AE
Antimicrob Agents Chemother; 1999 Aug; 43(8):1845-55. PubMed ID: 10428901
[TBL] [Abstract][Full Text] [Related]
8. In vitro antituberculosis activities of ACH-702, a novel isothiazoloquinolone, against quinolone-susceptible and quinolone-resistant isolates.
Pucci MJ; Ackerman M; Thanassi JA; Shoen CM; Cynamon MH
Antimicrob Agents Chemother; 2010 Aug; 54(8):3478-80. PubMed ID: 20516287
[TBL] [Abstract][Full Text] [Related]
9. In vitro biological evaluation of novel broad-spectrum isothiazolone inhibitors of bacterial type II topoisomerases.
Charrier C; Salisbury AM; Savage VJ; Moyo E; Forward H; Ooi N; Cheung J; Metzger R; McGarry D; Walker R; Cooper IR; Ratcliffe AJ; Stokes NR
J Antimicrob Chemother; 2016 Oct; 71(10):2831-9. PubMed ID: 27353465
[TBL] [Abstract][Full Text] [Related]
10. Antibacterial activity of novel dual bacterial DNA type II topoisomerase inhibitors.
D'Atanasio N; Capezzone de Joannon A; Di Sante L; Mangano G; Ombrato R; Vitiello M; Bartella C; Magarò G; Prati F; Milanese C; Vignaroli C; Di Giorgio FP; Tongiani S
PLoS One; 2020; 15(2):e0228509. PubMed ID: 32074119
[TBL] [Abstract][Full Text] [Related]
11. The anti-methicillin-resistant Staphylococcus aureus quinolone WCK 771 has potent activity against sequentially selected mutants, has a narrow mutant selection window against quinolone-resistant Staphylococcus aureus, and preferentially targets DNA gyrase.
Bhagwat SS; Mundkur LA; Gupte SV; Patel MV; Khorakiwala HF
Antimicrob Agents Chemother; 2006 Nov; 50(11):3568-79. PubMed ID: 16940059
[TBL] [Abstract][Full Text] [Related]
12. In vitro and in vivo activities of PD 0305970 and PD 0326448, new bacterial gyrase/topoisomerase inhibitors with potent antibacterial activities versus multidrug-resistant gram-positive and fastidious organism groups.
Huband MD; Cohen MA; Zurack M; Hanna DL; Skerlos LA; Sulavik MC; Gibson GW; Gage JW; Ellsworth E; Stier MA; Gracheck SJ
Antimicrob Agents Chemother; 2007 Apr; 51(4):1191-201. PubMed ID: 17261623
[TBL] [Abstract][Full Text] [Related]
13. Novel topoisomerase inhibitors: microbiological characterisation and in vivo efficacy of pyrimidines.
Uria-Nickelsen M; Neckermann G; Sriram S; Andrews B; Manchester JI; Carcanague D; Stokes S; Hull KG
Int J Antimicrob Agents; 2013 Apr; 41(4):363-71. PubMed ID: 23305654
[TBL] [Abstract][Full Text] [Related]
14. Dual-targeting properties of the 3-aminopyrrolidyl quinolones, DC-159a and sitafloxacin, against DNA gyrase and topoisomerase IV: contribution to reducing in vitro emergence of quinolone-resistant Streptococcus pneumoniae.
Okumura R; Hirata T; Onodera Y; Hoshino K; Otani T; Yamamoto T
J Antimicrob Chemother; 2008 Jul; 62(1):98-104. PubMed ID: 18390884
[TBL] [Abstract][Full Text] [Related]
15. In vivo pharmacodynamics of ceftobiprole against multiple bacterial pathogens in murine thigh and lung infection models.
Craig WA; Andes DR
Antimicrob Agents Chemother; 2008 Oct; 52(10):3492-6. PubMed ID: 18676887
[TBL] [Abstract][Full Text] [Related]
16. Exploration of the activity of 7-pyrrolidino-8-methoxyisothiazoloquinolones against methicillin-resistant Staphylococcus aureus (MRSA).
Kim HY; Wiles JA; Wang Q; Pais GC; Lucien E; Hashimoto A; Nelson DM; Thanassi JA; Podos SD; Deshpande M; Pucci MJ; Bradbury BJ
J Med Chem; 2011 May; 54(9):3268-82. PubMed ID: 21425851
[TBL] [Abstract][Full Text] [Related]
17. In vitro activity of nemonoxacin (TG-873870), a novel non-fluorinated quinolone, against clinical isolates of Staphylococcus aureus, enterococci and Streptococcus pneumoniae with various resistance phenotypes in Taiwan.
Chen YH; Liu CY; Lu JJ; King CH; Hsueh PR
J Antimicrob Chemother; 2009 Dec; 64(6):1226-9. PubMed ID: 19833635
[TBL] [Abstract][Full Text] [Related]
18.
Barman TK; Kumar M; Mathur T; Namba E; Singh D; Chaira T; Kurosaka Y; Yamada M; Upadhyay DJ; Masuda N
Antimicrob Agents Chemother; 2018 Jun; 62(6):. PubMed ID: 29610202
[TBL] [Abstract][Full Text] [Related]
19. [In vitro and in vivo antibacterial activities of pazufloxacin mesilate, a new injectable quinolone].
Nomura N; Mitsuyama J; Furuta Y; Yamada H; Nakata M; Fukuda T; Yamada H; Takahata M; Minami S
Jpn J Antibiot; 2002 Aug; 55(4):412-39. PubMed ID: 12378871
[TBL] [Abstract][Full Text] [Related]
20. Target preference of 15 quinolones against Staphylococcus aureus, based on antibacterial activities and target inhibition.
Takei M; Fukuda H; Kishii R; Hosaka M
Antimicrob Agents Chemother; 2001 Dec; 45(12):3544-7. PubMed ID: 11709337
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
